ABSTRACT
3
Our results suggest that resistant P. aeruginosa are selected in less than 10 days independently of the antimicrobial class. Different resistance mechanisms lead to loss or persistence of resistance after removal of the selecting agent.
Even if resistant isolates are not evident on culture, these may persist in the lung and can rapidly be reselected. 
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INTRODUCTION
Pseudomonas aeruginosa is one of the most important Gram-negative opportunistic pathogens responsible for severe ventilator-associated pneumonia (VAP) (45). VAP is a major medical problem responsible for high mortality and elevated costs in intubated patients (4, 7, 23, 34) . Prolonged endotracheal intubation, associated with exposure to antimicrobial therapies, frequently leads to colonization of the upper respiratory tract by P. aeruginosa Studies analyzing the longitudinal follow-up of colonized patients over prolonged time have been performed so far only in cystic fibrosis (CF) patients with respect to β-lactam resistance (12) . However no study has examined the overall resistance phenotypes and their underlying mechanisms in intubated patients. We therefore decided to follow prospectively patients at the intensive care units of the University Hospital Geneva.
The aims of the study were (i) to follow precisely the kinetics of emergence and persistence of resistance phenotypes, upon exposure to different classes of antimicrobials, (ii) to identify by gene expression analysis the resistance mechanisms acquired in response to particular antimicrobial treatments and (iii)
to establish a correlation between gene expression and antimicrobial susceptibility levels. Antimicrobial regimens. Antimicrobials were administered at standard regimens (37): imipenem (500 mg qid), piperacillin-tazobactam (4.5 g qid),
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tobramycin (1.7 mg/kg tid), cefepime (2g bid) and ciprofloxacin (400 mg tid).
The doses were adapted to the renal function during periods of significant reduction (< 40 ml/min) of the creatinine clearance.
Strain collection and susceptibility testing. Upon collection, all tracheal aspirates were transferred to ice without delay and directly transported to the research facility. The tracheal aspirates were immediately homogenized with dithiothreitol and aliquots spread on Pseudomonas isolation agar (Pseudosel, Becton Dickinson, Cockeysville, MD). For each aspirate, one to seven colonies or 272 (32) were used in the PCR reaction, the conditions of which were as follows: one cycle at 94 °C for 5 min, 45 cycles at 94 °C for 1 min, then 36 °C for 1 min and 72 °C for 2 min followed by one cycle of 72 °C for 10 min. patient was treated with non-invasive mechanical ventilation until day 23, the date of intubation (Fig. 1B) . In contrast to patient A, patient B did not experience P. aeruginosa VAP during the study period. Cefepime was administered from day 3 to day 6 for severe purulent bronchitis, followed by 14 days of ciprofloxacin (D4-D20) and cefepime (D33-D43). Because of the severity of respiratory insufficiency, extubation was impossible and the patient underwent tracheotomy before being transferred to another hospital. Despite repeated antimicrobial treatments, both patients remained colonized by P.

aeruginosa throughout the entire study period.
Timing of antimicrobial therapies and evolution of phenotypic resistance in isolates from tracheal aspirations. 18 tracheal aspirates were collected for both patients during a 3 months (patient A) and a 43 days (patient B)
observation period (Fig. 1) . To follow the sequential evolution of antimicrobial resistance of P. aeruginosa isolates, one to seven colonies were selected from each tracheal aspirate (see Material and Methods). The resistance profiles against antimicrobial agents are shown for a total of 40 isolates from patient A and a total of 69 isolates from patient B in Tables 1 and 2 .
Patient A did not receive any antimicrobial agents during the three weeks preceding the study period. suggesting that in this case maintenance of a significant number of clones resistant to piperacillin, but not to imipenem was dependent on continuing selective pressure. Markedly, 5 days after the initiation of the second combination-therapy, multidrug-resistant isolates reemerged (D68 in Fig. 1A ).
Again SCVs were present among these isolates. All isolates remained susceptible to quinolone antimicrobials ( Table 1 ), suggesting that efflux mechanisms were unlikely to be active in these isolates.
Patient B received cefepime for 8 days during the two weeks preceding the first detection of P. aeruginosa isolates in tracheal secretions. This therapy did however not select cefepime resistant isolates ( isolate were detected respectively on D36 and D43 (ten days after initiation of the therapy), during the third cefepime treatment. Interestingly, these two isolates remained susceptible to the six other β-lactams tested, suggesting that
resistance was not due to derepression of the chromosomal ampC β-lactamase, and resulted in one isolate (24F4) from overexpression of the MexXY efflux pump (data not shown) (16) .
Together these observations suggest that in both patients the exposure to various classes of antimicrobial agents was followed by the selection of resistant clones in 6 to 10 days. Strikingly, clones resistant to certain β-lactams and aminoglycosides appeared even in the absence of exposure to these antimicrobials. The persistence of resistant clones after discontinuation of the antimicrobial therapy varied depending on the selecting agent. Moreover SCVs were observed after exposure to aminoglycosides.
Appearance of new resistance phenotypes does not correlate with
colonization by new P. aeruginosa isolates. One explanation for the appearance of resistant clones in the absence of antimicrobial exposure could be cross-colonization with a new strain from another patient (41). We therefore determined whether resistant and susceptible clones were genotypically related, and performed RAPD analysis on 27 isolates from patient A (Table 1) , and 35 from patient B ( Table 2 ). The isolates were selected in such a manner that they covered the whole panel of resistance profiles. Isolates from patient A displayed an identical banding pattern and therefore belonged to the same RAPD genotype (d, Table 1 ). This result strongly suggests that all resistant isolates from this patient, including the multidrug resistant SCV, derived from
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on July 10, 2017 by guest http://aac.asm.org/ Downloaded from the same susceptible clone isolated initially from the bronchoalveolar lavage and not from the acquisition of a new P. aeruginosa strain (Fig. 1A) .
In patient B, three different RAPD types (a, b, and c) were detected among isolates collected during the first 12 days of the observation period ( Table 2 ).
All isolates recovered thereafter belonged to the RAPD type-a, demonstrating that all FQ-I and FQ-R isolates derived from a susceptible type-a clone.
Reanalysis of isolates from patient B with a second primer (208) confirmed the classification obtained with primer 272 (data not shown).
Expression of specific resistance mechanisms correlates with resistance
phenotypes. Resistance to carbapenems is frequently related to decreased expression or loss of the carbapenem specific porin OprD (47, 48). We therefore measured the expression of oprD in the isolates from patient A. With the exception of the initial imipenem-susceptible isolate, all other, imipenem resistant isolates showed decreased oprD expression compared to PAO1
(range: 0.4 to 0.01 fold). Resistance to meropenem was not linked to resistance to imipenem and appeared later during the study period. In contrast to imipenem, meropenem is a substrate of the MexAB-OprM efflux pump, however meropenem susceptibilities did not correlate with mexA expression, suggesting the presence of other meropenem-specific resistance mechanisms.
Strikingly OprD mutants persisted for at least two months in this patient despite discontinuation of imipenem therapy.
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Resistance to penicillins and cephalosporins is usually mediated by the inducible ampC β-lactamase present on the P. aeruginosa chromosome. We therefore analyzed by qRT-PCR the expression of this gene in 27 isolates (Table 1 ) from patient A and compared it to the one of the susceptible PAO1 reference strain. We observed a parallel evolution between phenotypic β-lactam resistance (expressed as 1/the inhibition zone) and the level of ampC expression in the different isolates collected during the 3 months study period (Fig. 2) . Indeed, in all isolates displaying a phenotypic resistance towards piperacillin-tazobactam, the expression of ampC was increased (20 to 5,000 fold). Plotting the ampC expression against piperacillin-tazobactam inhibition zone diameters revealed the presence of two populations, the more resistant one being mainly comprised of SCVs (Fig. 3A) . A good correlation was found between piperacillin-tazobactam ( Fig. 3A) , aztreonam ( Fig. 3B ) and ceftazidime resistance levels and ampC expression (Table 3) , incriminating AmpC as the major resistance determinant in these isolates. A threshold level for ampC expression of 20-25 fold as compared to the PAO1 reference strain allowed to discriminate between cephalosporin/penicillin-susceptible and resistant isolates ( Fig. 3A and 3B ).
Resistance to aminoglycosides in P. aeruginosa can result from their enzymatic inactivation or from their extrusion by the MexXY efflux pump. Although we observed a more than 20-fold overexpression in two of the 11 aminoglycoside resistant isolates from patient A, there was no general correlation between resistance and expression of this efflux pump (data not shown). This supports found however between FQ resistance levels and mexC expression: all FQ-I and FQ-R isolates overexpressed this gene (Fig. 3D , Table 4 ). The expression levels of oprJ and of the regulator gene nfxB also correlated with the FQ resistance levels (Table 4) Isolates resistant to imipenem and to piperacillin emerged at the latest 6 days after initiation of therapy. All imipenem-resistant isolates showed decreased oprD expression. However, the fold oprD decrease did not correlate well with imipenem susceptibility levels, suggesting that additional factors such as the involvement of post-transcriptional regulation of oprD (9) or the interplay with
AmpC expression might play a role as suggested previously (28).
Resistance to penicillins and cephalosporins in P. aeruginosa can be mediated by the chromosomal AmpC β-lactamase or the MexAB-OprM efflux pump (33).
In patient A, piperacillin-tazobactam therapy selected resistant isolates characterized by derepressed ampC expression rather than MexAB-OprM overproduction. These isolates were also resistant to ceftazidime and aztreonam. Indeed, susceptibilities for these β-lactams correlated with ampC expression levels, which might be explained by the fact that both compounds, though weak inducers of ampC, are nevertheless hydrolyzed by this enzyme when expressed at high levels (2, 27). Since ampC expressions were (14) . SCVs are hyperpiliated and exhibit increased twitching motility and increased capacity to form biofilms (14) . To date, such SCVs have been isolated only from CF patients, and our study shows for the first time that SCVs can also be isolated from a non-CF environment. As described previously, SCVs emerge under aminoglycoside treatment, either in vitro with gentamicin (25), or in vivo with tobramycin as in our case (13) . In the lung environment, SCVs seemed to be out competed by the wild-type morphotype in the absence of selective pressure. They remained however present in the lung reservoir since they were reselected rapidly during the following combination therapy. SCVs present a serious risk for the Our study further shows that independent of the antimicrobial treatment administered, acquisition of resistance determinants was not due to crosscolonization with new P. aeruginosa strains but to mutations occurring in an originally susceptible strain colonizing the patient for prolonged periods (over 90 days for patient A). Relapse of P. aeruginosa infections with single strains persisting for prolonged periods has been documented (41), and these results underline the importance for developing methods to reduce persistent colonization.
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All mechanisms identified in these isolates were chromosomally encoded underlining the intrinsic capacities of this organism to develop resistance.
Interesting differences were observed between the type of resistance mechanism and the persistence of the corresponding isolate in the absence of antimicrobial agents. Whereas both imipenem and fluoroquinolone resistant isolates were detected in the tracheal aspirates for prolonged periods after treatment discontinuation, β-lactam resistant isolates rapidly became undetectable, but reappeared upon re-exposure to β-lactam antimicrobials in a short time. This suggests that ampC overexpression has a more pronounced impact on P. aeruginosa fitness than OprD loss or MexCD-OprJ overexpression. As a result persistence of imipenem and fluoroquoinolone resistant clones might be visible to the clinician, while β-lactam resistant isolates with derepressed ampC might escape surveillance. This is of major importance when therapies are given for VAP, since inappropriate antimicrobial therapies are associated with an increased mortality (3, 18) . Together these data strongly support our previous observations (1) that clinicians should be extremely cautious in the choice of antimicrobial agents when a P. aeruginosa infection is suspected, and avoid using classes of antimicrobials to which their patients have been exposed during the previous months (41).
Recently the standard duration of treatment of VAP of 14-21 days has been challenged (5, 36). It has been suggested that reducing the treatment duration to 8 days might be able to prevent the selection of resistant isolates without negatively impacting on the clinical outcome (6). Our results support this However whether shorter treatment durations can be used for P. aeruginosa VAP without increasing the risk for recurrent infections is unclear and deserves further studies (6).
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GENERAL CONCLUSIONS
Our study was limited to the analyses of only two patients; therefore it is difficult to draw general conclusions from our observations. However we believe that 
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